12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zerenex ferric citrate: Phase II started

Keryx began a placebo-controlled, U.S. Phase II trial to evaluate Zerenex for 12 weeks in about 150 anemic patients with stage III-V non-dialysis dependent CKD. The compound is in Phase III testing to treat hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis....

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >